西妥昔单抗超敏反应患者脱敏成功：一例报告
Successful desensitization of a patient with cetuximab hypersensitivity: A case report.
作者信息
Solduzian Mohammad, Anvari Saeed, Taghvaye Masoumi Hamidreza, Shahi Farhad, Jahangard-Rafsanjani Zahra
机构信息
1 Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
2 Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran.
出版信息
J Oncol Pharm Pract. 2019 Oct;25(7):1726-1730. doi: 10.1177/1078155218793505. Epub 2018 Aug 24.
BACKGROUND
Severe hypersensitivity reaction is a dangerous adverse drug reaction in patients receiving cetuximab. It requires drug discontinuation and medical management.
CASE DESCRIPTION
A 48-year-old man, previously diagnosed with metastatic colorectal cancer, was admitted for therapy continuation. During the first infusion of cetuximab, the patient experienced acute signs of hypersensitivity reactions. The treatment team decided to administer cetuximab employing the desensitization protocol.
CONCLUSIONS
This study reports a severe hypersensitivity reaction to cetuximab in an adult patient with colorectal cancer. This patient was successfully managed with a new safe and rapid desensitization protocol.
背景
严重过敏反应是接受西妥昔单抗治疗的患者中一种危险的药物不良反应。它需要停药并进行医疗处理。
病例描述
一名48岁男性，先前被诊断为转移性结直肠癌，因继续治疗入院。在首次输注西妥昔单抗期间，患者出现了过敏反应的急性症状。治疗团队决定采用脱敏方案给予西妥昔单抗。
结论
本研究报告了一名成年结直肠癌患者对西妥昔单抗发生的严重过敏反应。该患者通过一种新的安全快速脱敏方案得到了成功处理。
Zotero 插件